Mihai Gheorghiade
Overview
Explore the profile of Mihai Gheorghiade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
555
Citations
22333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parrinello G, Greene S, Torres D, Alderman M, Bonventre J, Di Pasquale P, et al.
Heart Fail Rev
. 2021 Apr;
26(6):1529.
PMID: 33913077
No abstract available.
2.
Cunningham J, Ferreira J, Deng H, Anker S, Byra W, Cleland J, et al.
JACC Heart Fail
. 2020 Mar;
8(5):359-368.
PMID: 32171760
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevated natriuretic peptides for inclusion in the COMMANDER-HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban...
3.
Butler J, Khan M, Anker S, Fonarow G, Kim R, Nodari S, et al.
J Card Fail
. 2020 Feb;
26(5):429-437.
PMID: 32068002
Background: Elamipretide, a novel mitochondrial modulating agent, improves myocardial energetics; however, it is unknown whether this mechanistic benefit translates into improved cardiac structure and function in heart failure (HF) with...
4.
Baman J, Knapper J, Raval Z, Harinstein M, Friedewald J, Maganti K, et al.
Clin J Am Soc Nephrol
. 2019 Sep;
14(11):1670-1676.
PMID: 31554619
The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered....
5.
Knapper J, Raval Z, Harinstein M, Friedewald J, Skaro A, Abecassis M, et al.
J Cardiovasc Med (Hagerstown)
. 2018 Dec;
20(2):51-58.
PMID: 30540647
: Patients with end-stage renal disease (ESRD) undergoing evaluation for kidney and/or pancreas transplantation represent a population with unique cardiovascular (CV) profiles and unique therapeutic needs. Coronary artery disease (CAD)...
6.
Marti C, Fonarow G, Anker S, Yancy C, Vaduganathan M, Greene S, et al.
Eur J Heart Fail
. 2018 Dec;
21(3):286-296.
PMID: 30537163
Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice...
7.
Dungen H, Kober L, Nodari S, Schou M, Otto C, Becka M, et al.
Clin Pharmacol Drug Dev
. 2018 Nov;
8(7):942-951.
PMID: 30452784
The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI)....
8.
Voors A, Shah S, Bax J, Butler J, Gheorghiade M, Hernandez A, et al.
Eur J Heart Fail
. 2018 Sep;
20(11):1601-1610.
PMID: 30225882
Despite major advances in the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF), morbidity and mortality associated with the condition remain high, suggesting the need for additional...
9.
Hamo C, OConnor C, Metra M, Udelson J, Gheorghiade M, Butler J
J Card Fail
. 2018 Sep;
24(11):783-792.
PMID: 30217774
The prevalence of heart failure continues to grow, and this is accompanied by an increase in hospitalization for acute heart failure. Hospitalization for heart failure results in a trajectory shift...
10.
Zannad F, Anker S, Byra W, Cleland J, Fu M, Gheorghiade M, et al.
N Engl J Med
. 2018 Aug;
379(14):1332-1342.
PMID: 30146935
Background: Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and...